A successful outcome to the Phase II pilot trial will also meet one of the key requirements to progress discussions with Novartis Animal Health/Elanco regarding the Option Agreement.
$2.6m cash at hand and Debt Free with no loans or liabilities.
BRI will flavour the product and increase efficacy.
Ann: Appendix 4C - Quarterly Report & Brief Company Update, page-4
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.81M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 19.0¢ | $212.6K | 1.118M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7234 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 260069 | 3 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |